Genome-wide association studies identify genetic determinants of synucleinopathy biomarkers
The present study reveals established and novel genetic modulators of potential α-synucleinopathy biomarkers, demonstrating that genetic background significantly shapes biomarker levels. These genetic influences should be accounted for when conducting biomarker-based research, clinical trials, or therapeutic development to ensure accurate interpretation and improve their translational relevance.
Authors
- Michael Ta (ORCID: https://orcid.org/0000-0001-6148-3841)
- Emma N. Somerville (ORCID: https://orcid.org/0000-0002-5892-8069)
- Hirotaka Iwaki (ORCID: https://orcid.org/0000-0002-8982-7885)
- Ziv Gan-Or
- Konstantin Senkevich
- Roy N Alcalay
- Lang Liu
Institutions
- Montreal Neurological Institute and Hospital (CA)
- Tel Aviv University (IL)
- Columbia University Irving Medical Center (US)
- Tel Aviv Sourasky Medical Center (IL)
- National Institute on Aging (US)
- McGill University (CA)
Publication Details
- Journal
- medRxiv
- Published
- 2025-12-30
- DOI
- https://doi.org/10.64898/2025.12.29.25343142
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Michael J. Fox Foundation for Parkinson's Research
- McGill University
- Consortium canadien en neurodégénérescence associée au vieillissement
- Canada First Research Excellence Fund